Moberg Pharma appoints new General Manager of U.S. business

Moberg Pharma AB (OMX: MOB) announces that Jeff Vernimb has been appointed
General Manager for its U.S. operations and a member of Moberg’s Management Team
– effective from December 15, 2014. Jeff Vernimb brings more than 25 years of
experience in consumer health products marketing and sales across multi-national
and smaller entrepreneurial businesses.
Prior to his position with Moberg, Jeff Vernimb was Vice President of Sales and
a member of the Senior Management Team with Insight Pharmaceuticals. In addition
to his position at Insight, he has held senior level positions at Dynova
Laboratories, Cardinal Health, Novartis Consumer and Pfizer/Warner Lambert. His
experience includes extensive brand management, Rx to OTC switch and customer
marketing roles. He started his career in Sales with The Mennen Company.

“It is a pleasure to welcome Jeff to the Management Team at Moberg. I look
forward to working together to continue driving the growth of our U.S.
business,” said Peter Wolpert, CEO of Moberg Pharma AB.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.45 am(CET) on November 20, 2014.
For additional information contact:
Peter Wolpert, CEO
Telephone: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergpharma.se

Peter Östling, IR
Mobil: +46 (0)76 – 314 09 78
Email: peter.ostling@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
a direct sales and marketing organization in the U.S. and an extensive
distributor network in more than 40 countries. The company’s OTC portfolio
includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®,
and Fergon®. Kerasal Nail® (Nalox™ in certain ex-U.S. markets) is the leading
product for the treatment of nail disorders in the U.S. and Nordic market. The
current portfolio will be supplemented by the acquisition and in-licensing of
additional products as well as product development with a focus on innovative
drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and
New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list
of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please
visit: www.mobergpharma.com.